Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

The New England Journal of Medicine - In patients with untreated metastatic melanoma, the addition of ipilimumab (anti-CTLA4) to nivolumab (anti-PD1) did not further improve response rate or progression-free survival in PD-L1

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Cancers, Free Full-Text

PDF) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Nivolumab and Relatlimab for Advanced Melanoma - NCI

Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis